Informazioni sui membri
Dr Marta Morales Ballús
Spagna
Team
Dr Jaume Català Mora
Spagna
Dr Elisa Carreras
Spagna
Dr Itziar Alonso
Spagna
Dr Isabel Ayet
Spagna
Dr Ester Casas
Spagna
Optometrist Ana Díaz
Spagna
Dr Jesús Díaz
Spagna
Optometrist Enric Puigventos
Spagna
Optometrist Carles Fresno
Spagna
Dr Carmen García Vicuña
Spagna
Dr Hugo Gonzalez
Spagna
Optometrist Enrique Jimenez
Spagna
Dr Ana Llorca
Spagna
Dr Antonio Federico Martinez Monstseny
Spagna
Dr Joan Prat
Spagna
Dr Gemma Romeu
Spagna
Dr Alicia Serra
Spagna
Optometrist Simone Suh
Spagna
Dr Mariona Vidal
Spagna
Optometrist Begoña Yeste
Spagna
Dr Núria Planas
Spagna
Centro HCP
contatti
Hospital Sant Joan de Déu, Spain
Test clinici
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation